We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




OraSure Technologies to Purchase DNA Genotek for US$53 Million

By LabMedica International staff writers
Posted on 01 Aug 2011
OraSure Technologies, Inc. More...
(Bethlehem, PA, USA) will acquire privately held DNA Genotek Inc. (Ottawa, Canada), a leading provider of oral fluid sample collection, stabilization, and preparation products for molecular diagnostic applications. The transaction valued at approximately US$53 million is anticipated to close in the third quarter of 2011.

The acquisition of DNA Genotek will strengthen OraSure’s leadership in oral fluid diagnostics, by providing a complementary portfolio of products that enable easy and reliable collection, stabilization, transportation, and storage of high quality nucleic acid (DNA and RNA) samples. These samples can then be used for a wide range of diagnostic and research applications.

The Oragene•DNA sample collection kit is DNA Genotek's lead product, providing an all-in-one system for the collection, stabilization, transportation and purification of DNA from saliva. Genetic samples are collected using a simple, noninvasive method; collected samples may be transported and stored for extended periods at ambient temperatures.

DNA Genotek products are used in clinical genetic testing, pharmacogenomics, personalized medicine, academic research, animal genetics, and livestock genetics markets. DNA Genotek is a leading provider of oral fluid collection devices to the direct-to-consumer personal genetics testing market. The company supplies products that provide substantial advantages over traditional methods of sampling such as blood or buccal swabs.

OraSure Technologies is a leader in the development, manufacture, and distribution of oral fluid diagnostic devices and other technologies designed to diagnose critical medical conditions and diseases. Its innovative products include rapid tests for the detection of antibodies to Human Immunodeficiency virus (HIV) and Hepatitis C virus (HCV) at the point of care (POC) and testing solutions for detecting various drugs of abuse.

OraSure’s products are sold globally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.

Related Links:

OraSure Technologies, Inc.
DNA Genotek Inc.



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.